| Project/Area Number |
17K11137
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
那須 保友 岡山大学, 医歯薬学総合研究科, 教授 (20237572)
荒木 元朗 岡山大学, 大学病院, 講師 (90467746)
植木 英雄 岡山大学, 医学部, 技術専門職員 (90537218)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 癌免疫 / チェックポイント阻害薬 / REIC/Dkk-3 |
|---|
| Outline of Final Research Achievements |
The regulation of immune system is very important for cancer treatment. Recently, dramatic anti-tumor effects have been reported in the patients receiving immune checkpoint inhibitors. However, they alone do not eradicate cancer. Even if they are effective, there are concerns about side effects. In the future, there is a need for a method of controlling immune function that has a similar therapeutic effect with fewer side effects. To date, our group has demonstrated that the type 2 diabetes drug metformin has similar effects to the above antibodies. In this study, we aim to elucidate the mechanism of immune exhaustion release by a novel checkpoint inhibitor and to establish new approach for the combined immunotherapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
本申請研究では、既に臨床に応用されている免疫チェックポイント阻害薬とメトホルミン併用することにより、従来の免疫治療では想像もできなかったレベルでの抗癌治療効果が期待できる。すなわち本研究を推進することで、様々な癌腫に応用可能な新規の複合免疫療法が確立されることが期待される。次世代の免疫治療にチャレンジするという点で、本研究の重要性、意義は計り知れない。
|
